ClinicalTrials.gg
Active, not recruitingNCT04529772ESCALADEUpdated Oct 13, 2026

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)

A Phase 3 interventional study of acalabrutinib and placebo in Diffuse Large B-Cell Lymphoma, sponsored by Acerta Pharma BV. Active, not recruiting at 245 sites in 23 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Updated Oct 13, 20262 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
611
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse — 5 open to participants now, 12 under way, 2 of them phase 3. acalabrutinib · Lymphoma, Large B-Cell, Diffuse.

Enrollment
Largest of 15
611 · median 72
Started
2020
with 2 others
Phase 3
2 of 15
1 open now
Primary completion
2027-02
later than 4 of 11 live
Registered
8th of 15
by date
Lead sponsor
2 of 15
Acerta Pharma BV

Among the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, this one has the largest enrollment, is one of 3 that started in 2020, is one of 2 in phase 3, reaches primary completion later than 4 of the 11 other live ones, and was the 8th registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

5 of the 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies testing acalabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

Phase 3 randomized, double-blind, placebo-controlled, study assessing the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) vs placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma.

Read the detailed description

Phase 3 randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of acalabrutinib plus rituximab,cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as compared with placebo plus R-CHOP in subjects ≤75 years of age with previously untreated non-germinal center diffuse large B-cell lymphoma (activated B-cell (ABC) and unclassified).

03

Conditions studied

  • Diffuse Large B-Cell Lymphoma

Keywords

  • Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse
  • Neoplasms
  • Lymphoproliferative Disorders
  • Lymphatic Diseases
  • Lymphoma, Non-Hodgkin
  • Prednisone
  • Cyclophosphamide
  • Rituximab
  • Doxorubicin
  • Vincristine
  • Acalabrutinib
  • Calquence
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women, age ≥18 and ≤75 years
  • confirmed DLBCL, sufficient diagnostic material should be available to forward to a central laboratory for gene expression profiling and pathology review.
  • No prior treatment for DLBCL
  • (ECOG) performance status of ≤ 2.
  • International Prognostic Index (IPI) score of 1 to 5
  • Disease Stage II to IV by the Ann Arbor Classification
  • Adequate organ and marrow function
  • Agreement to use highly effective forms of during the study and 12 months after the last dose of rituximab

Exclusion criteria

Exclusion Criteria:

  • Evidence of severe or uncontrolled systemic diseases
  • Known history of a bleeding diathesis (i.e., haemophilia, von Willebrand disease)
  • History of stroke or intracranial haemorrhage in preceding 6 months.
  • Known CNS lymphoma or
  • Known primary mediastinal lymphoma
  • Known High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
  • Prior history of indolent lymphoma or CLL
  • History of or ongoing confirmed PML
  • Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of first dose of study drug, or any Class 3 or 4 cardiac disease as defined by the Functional Classification
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach, extensive small bowel resection that is likely to affect absorption, symptomatic inflammatory bowel disease, partial or complete bowel obstruction, or gastric restrictions and bariatric surgery, such as gastric bypass.
  • Uncontrolled active systemic fungal, bacterial, viral, or other infection
  • Prior anthracycline use ≥150 mg/m2
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
611 participants (actual)

Study arms

  • Experimental
    acalabrutinib + R-CHOP

    Acalabrutinib plus Rituximab, Cyclosphosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)

    Drug: acalabrutinib · Drug: Prednisone · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Vincristine · Drug: Doxorubicin

  • Placebo comparator
    placebo + R-CHOP

    Placebo plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP)

    Drug: placebo · Drug: Prednisone · Drug: Rituximab · Drug: Cyclophosphamide · Drug: Vincristine · Drug: Doxorubicin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) per the Lugano Classification for NHL in Arm A compared to Arm B

    Time frame: at every single visit up to 60 months

Secondary outcomes

  1. Investigator-assessed event-free survival (EFS) for NHL in Arm A compared to Arm B

    Time frame: at every single visit up to 60 months

  2. Overall survival in Arm A compared to Arm B

    Time frame: at every single visit up to 60 months

  3. Percentage of Participants Who Achieved a Complete Response (CR) per 2014 Lugano Classification for NHL

    Time frame: at every single visit up to 60 months

07

Study locations

245 sites
  • Research Site
    Tucson, Arizona 85711, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Irvine, California 92618, United States
  • Research Site
    Aurora, Colorado 80012, United States
  • Research Site
    Norwich, Connecticut 06360, United States
  • Research Site
    Fort Myers, Florida 33901, United States
  • Research Site
    Orlando, Florida 32804, United States
  • Research Site
    St. Petersburg, Florida 33705-1449, United States
  • Research Site
    Tallahassee, Florida 32308-5304, United States
  • Research Site
    West Palm Beach, Florida 33401, United States
  • Research Site
    Fort Wayne, Indiana 46845, United States
  • Research Site
    Des Moines, Iowa 50309, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Louisville, Kentucky 40207, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Grand Rapids, Michigan 49503, United States
  • Research Site
    Minneapolis, Minnesota 55407, United States
  • Research Site
    St Louis, Missouri 63129, United States
  • Research Site
    Albany, New York 12208, United States
  • Research Site
    New York, New York 10028, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Stony Brook, New York 11795, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Eugene, Oregon 97401, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Philadelphia, Pennsylvania 19111, United States
  • Research Site
    Pittsburgh, Pennsylvania 15212, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Fort Sam Houston, Texas 78234, United States
  • Research Site
    Lubbock, Texas 79410, United States
  • Research Site
    Salem, Virginia 24153, United States
  • Research Site
    Adelaide, 5000, Australia
  • Research Site
    Camperdown, 2050, Australia
  • Research Site
    Darlinghurst, 2010, Australia
  • Research Site
    Heidelberg, 3084, Australia
  • Research Site
    Hobart, 7000, Australia
  • Research Site
    Kogarah, 2217, Australia
  • Research Site
    Nedlands, 6009, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Linz, 4021, Austria
  • Research Site
    Wels, 4600, Austria
  • Research Site
    Antwerp, 2060, Belgium
  • Research Site
    Bruges, 8000, Belgium
  • Research Site
    La Louvière, 7100, Belgium
  • Research Site
    Goiânia, 74605-020, Brazil
  • Research Site
    Passo Fundo, 99010-260, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    Porto Alegre, 90619-900, Brazil
  • Research Site
    Ribeirão Preto, 14051-140, Brazil
  • Research Site
    Rio de Janeiro, 22793-080, Brazil
  • Research Site
    São Paulo, 01236-030, Brazil
  • Research Site
    São Paulo, 01509-900, Brazil
  • Research Site
    São Paulo, 04029-000, Brazil
  • Research Site
    São Paulo, 08270-070, Brazil
  • Research Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Research Site
    Toronto, CA M5G 2M9, Canada
  • Research Site
    Winnipeg, Manitoba R3E 0V9, Canada
  • Research Site
    London, Ontario N6A 5W9, Canada
  • Research Site
    Lévis, Quebec G6V 0B8, Canada
  • Research Site
    Montreal, Quebec H1T 2M4, Canada
  • Research Site
    Montreal, Quebec H2X 3E4, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Ottawa, K1H 8L6, Canada
  • Research Site
    Toronto, M4N 3M5, Canada
  • Research Site
    Beijing, 100044, China
  • Research Site
    Beijing, 100191, China
  • Research Site
    Changchun, 130021, China
  • Research Site
    Chengdu, 610041, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510080, China
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Hangzhou, 310003, China
  • Research Site
    Hangzhou, 310009, China
  • Research Site
    Harbin, 150081, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Luoyang, 471003, China
  • Research Site
    Nanchang, 330006, China
  • Research Site
    Nanning, 530021, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shanghai, China
  • Research Site
    Shenyang, 110004, China
  • Research Site
    Shenyang, 110042, China
  • Research Site
    Shijiazhuang, 050020, China
  • Research Site
    Suzhou, 215004, China
  • Research Site
    Tianjin, 300020, China
  • Research Site
    Tianjin, 300060, China
  • Research Site
    Wuhan, 430022, China
  • Research Site
    Wuhan, 430030, China
  • Research Site
    Xiamen, 361003, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Hradec Králové, 500 05, Czechia
  • Research Site
    Ostrava - Poruba, 708 52, Czechia
  • Research Site
    Pilsen, 304 60, Czechia
  • Research Site
    Prague, 100 34, Czechia
  • Research Site
    Prague, 128 08, Czechia
  • Research Site
    Brest, 29609, France
  • Research Site
    Caen, 14033, France
  • Research Site
    Marseille, 13385, France

Showing the first 100 of 245 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2020 (actual). Primary completion is estimated for Feb 2027, 76 months after the start.

Of 37 industry-sponsored phase 3 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 82. This study's planned 76 months is above that.

Counting every sponsor, half of 73 studies reached it within 57 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Aug 28, 2020
StartActual
Oct 8, 2020
Primary completionEst.
Feb 22, 2027
CompletionEst.
Feb 22, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added
Show 2 added (1 Australia, 1 Belgium)
  • Research Site · Adelaide, Australia
  • Research Site · La Louvière, Belgium
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    2 sites added
    Show 2 added (1 Australia, 1 Belgium)
    • Research Site · Adelaide, Australia
    • Research Site · La Louvière, Belgium
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04529772
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Oct 8, 2020
Primary completion
Feb 22, 2027 (estimated)
Completion
Feb 22, 2027 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion